MAY 2 0 2002



MAY 2 1 2002

Approved for use through 143 (2012) DMP 063 4003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	09/663,600	
INFOR	KMAHON	N DISC	LOSURE	Filing Date	September 15, 2000	
STATEMENT BY APPLICANT				First Named Inventor	DUMAS MILNE EDWARDS, et al.	
				Art Unit	1646	
(use as many sheets as necessary)			cessary)	Examiner Name	Eileen B. O'Hara	
Sheet 1 of 3		Attorney Docket Number	31.US3.CIP			

	U.S. PATENT DOCUMENTS						
Examiner Initials		Document Number Number - Kind Code ² (<i>if known</i>	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
·		US-		A-A			
		US-					
parament when the set from the set of the se		US-	·				
·····		US-					
		US-					
		US-					
g vice-instruction which may be subject.		US-					
	ingle-sile (1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	US-					
		US-					
ingellingsjoch ter dreid.		US-					
		US-					
د، ودولتكاور ب بالجد 1464		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			**************************************		
		US-			- The state of the		

		FORE	IGN PATENT D	OCUMENTS	- · · · - · · · · · · · · · · · · · · ·	
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
-	N	WO 97/07198 - A2	- 02/27/1997	Genetics Institute Inc	X4	
	-	WQ-98/45436A2	10/15/1998	Genetics-Institute Inc:-	1:00	
(See Charles	_C_	WO-99/06548 - A2	02/11/1999	Genset	\	
ggs-fr	ยDag		05/27/1999	<u></u> Genset ™	Dogo	
*	E	WO 00/12708 - A2	~ 03/09/2000	Genentech find:		
Market and the same of	F	WO 00/18915 - A2	Maria 04/06/2000	Incyte Pharmaceuticals.		
Property of	Ğ	WO'00/26360 - A1	··· 05/11/2000	Adherex-Lechnologies		
EM	Н	WO 96/34981 - A	11/07/1996	Genset	abota A	·
EM	-	EP 0 625 572 - A	11/23/1994	Kanagawa Acad of Sci.		

Examiner Signature	Elen B. O Home	Date Considered	7/26/02
" :			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if KnownTECH CENTER 1600/2900

contrepnumos..

CONTREPNUMOS.. INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of 3 Sheet

09/663.600 **Application Number** September 15, 2000 Filing Date **DUMAS MILNE EDWARDS. et al.** First Named Inventor 1646 **Group Art Unit** Eileen B. O'Hara **Examiner Name Attomey Docket Number** 31.US3.CIP

	, _	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	ĭ
lagrana, delta mare		FURUSE, et al.; "Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No "Següénce"Similarity-to-Occludin";-The Journal of Cell Biology; Vol::141; No::7//June-29;:1998,:pp.,1539,1550; The Rockefeller University Press, 0021-9525/98/06/15391/12	
المعارض والمعارض والم	K	FURUSE, et al.; "Manner of Interaction of Heterogeneous Claudin Species Within and Between Tight Junction Strands", The Journal of Cell Biology, Vol. 147 No. 43 November 15: 1999; pp: 891: 908; The Rockefeller University Press, 0021-9525/99/11/891/13	
		KATAHIRA, et al.; "Molecular Cloning and Functional Characterization of the Receptor for Clostridium perfringens Enterotoxin", The Cournal of Cell Biology, Vol. 136, No. 6, March 24, 19997, pp. 1239-1247; The Rockefeller University Press, 0821-9525/97/03/1239/9	
د هنده مین مینود در این است. مینود و نواند مینود مینود مینود	ma ^M .c.	KINUGASA, et al.; "Claudins Regulate the Intestinal Barrier inResponse to Immune Mediators"; Gastroenterology 2000; Vol. 118; pp. 1001-1011; The American Gastroenterological Association; 0016-5085/00	
en a salan di salan d	: 24 K P-4-	LIPPOLDT, et al.; "Organization of choroid plexus epithelial and endothelial cell tight junctions and regulations of "claudin-1,"-2 and -5 expression by protein kinase C"; Molecular Neuroscience; NeuroReport, Vol. 11, No.7, pp	
	ಾಂ≥	LOCKHART, et al.; "Expression monitoring by hybridizationto high-density oligonucleotide arrays"; Research Article; Nat Biotechnol. 14(13):1675-80; Rublished on Dec 1996; p.1675-1680; XP-002074420	
The special section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a second section in the second section in the second section is a section in the second section in the second section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the s	*Ep->	TASHIRO, et al.; "Signal Sequence Trap: A Claning Strategy for Secreted Proteins and Type 1 Membrane Proteins"; Science; Vol. 261, July 30, 1993; pp.640-593; XP-000673204	
	Q	YOKOYAMA-KOBAYASHI, et al.; "A signal sequence detection system using secreted protease activity as an indicator"; Gene, Vol. 163 (1995), pp. 193-196; Elsevier Science, B.V.; SSDI 0378-11 19(95)00322-3	
	R	Accession No. AAG17984; Claudin-2, Homo Sapiens, Database: genbank; GU, J.R., et al.; submitted August 1999; "Novel human-cDNA:clone with function of Inhibiting cancer dell growth", Unpublished	
-1	8	Accession No. AAC27079; Claudin-2, Mus muscules; Darabase: Gel bank; FURUSE, et al.; submitted June 15, "1998; "Claudin-1-and -2; Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin"; J. Cell Biol. 141-(7); 1539-1550 (1998)	
	Ţ	Accession No. T03538; Bento Soares Homo sapiens cDNA clone IB43; Database: EMBL; SIKELA, J.M.; submitted September 21, 1992	

Examiner Signature	ilean B.O Hara	Date Considered	726/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

PTO(SB(08B (10,01)) 002
Approved for use through 10/31/2002 0 MB 0681-003 2 002
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paper ork Reduction Act control number. of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB TEAL CENTER 1600

Complete if Known Substitute for form 1449B/PTO 09/663.600 **Application Number** INFORMATION DISCLOSURE Filing Date September 15, 2000 **DUMAS MILNE EDWARDS. et al.** STATEMENT BY APPLICANT **First Named Inventor** 1646 **Group Art Unit** Eileen B. O'Hara (use as many sheets as necessary) **Examiner Name** Sheet 3 **Attorney Docket Number** 31.US3.CIP 3 of

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
>		Accession No. AA057573; Homo sapiens cDNA clone IMAGE:381523; Database: EMBL; WILSON; submitted September 6, 1996	
	1	dicates do not prost	
and the second	Section (Control of the Control of t	Accession No., N57409; Homo stpices cDIVA clone IMAGE:258726; Database; EMBL: WILSON; submitted February 22, 1996	
EA	w	CARNINCI, et al.; "High-efficiency full-length cDNA cloning by biotinylated CAP trapper"; Genomics, 37(3):327-36; November 1, 1996; PMID:8938445	
ENA	×	KATO, et al.; "Construction of a human full-length cDNA bank"; Gene, 150(2):243-50; December 15, 1994; PMID:7821789	
ETA.	Y	VON HEIJNE, G.; "A new method for predicting signal sequence cleavage sites"; Nucleic Acids Res. 14(11):4683-90; published June 11, 1986; PMID:3714490	
GA	Z	NOMURA, N., et al.; "Predictionof the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1"; DNA Res. 1(1):27-35; published in 1994; PMID:7584026	Hatamana
GA	AA	ADAMS, M.D., et al.; "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence"; Nature 377 (6547 Suppl):3-174; published September 28, 1995; PMID:7566098	
GA	AB	HILLIER, L.D., et al.; "Generation and analysis of 280,000 human expressed sequence tags"; Genome Res. 6(9):807-28; published September 1996; PMID:8889549	
Canada de Caración			
and the materials of the company of the same of the sa			

Evaminar	\cap	1 1.		A 4
Examiner		/4 × 1/	[Date [9/2//
O : 1		F) (() Nana	1 - 5.1.5	1126/02
L Signature	(Man		Considered	77 10
			Johnston	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.